久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • FDA agrees to review Pfizer’s NDAs for tafamidis pharmaceutical-technology
    January 16, 2019
    The US Food and Drug Administration (FDA) has accepted Pfizer’s two new drug applications (NDAs) for tafamidis to treat transthyretin amyloid cardiomyopathy (ATTR-CM).....
  • Pfizer’s tafamidis reduces risk of death by 30 %, reveals study expressbpd
    August 29, 2018
    Pfizer has anounced that the recent study has revealed, tafamidis drug reduced the risk of death for patients with a rare and fatal heart disease by around 30 per cent, boosting the prospects of what could be a billion-dollar-a-year drug.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service